Dalvance Injection, Powder, For Solution
Product Images NDC 57970-100

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Dalvance (NDC 57970-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dalvance 01

Chemical structure diagram of Dalbavancin, showing its detailed molecular composition with the labeled side chains R1 and R2, and the hydrochloride (HCl) component.*

FDA Label Image

Dalvance 02

A line graph showing Dalbavancin plasma concentration (mg/L) over time in days, with values plotted from Day 1 to Day 29. The graph includes error bars representing standard deviation, illustrating the decline in plasma concentration following intravenous administration of Dalbavancin injection, powder for solution, 500 mg/25 mL.*

FDA Label Image

Dalvance 03

Packaging label for Dalvance (dalbavancin) injection, 500 mg per vial, powder for solution for intravenous infusion. The label indicates it is a sterile single-use vial. Manufactured by Durata Therapeutics U.S. Limited, with instructions to discard unused portion. The label includes storage and reconstitution guidelines and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.